Asian Journal of Pharmaceutical Sciences最新文献_第5页

Multifunctional Prussian blue nanoparticles loading with Xuetongsu for efficient rheumatoid arthritis therapy through targeting inflammatory macrophages and osteoclasts 负载血通素的多功能普鲁士蓝纳米颗粒通过靶向炎性巨噬细胞和破骨细胞有效治疗类风湿关节炎

IF 10.7 1区医学 Q1 PHARMACOLOGY & PHARMACY

Asian Journal of Pharmaceutical Sciences

Pub Date : 2025-02-22 DOI: 10.1016/j.ajps.2025.101037

Yasi Deng , Bin Li , Hao Zheng , Ling Liang , Yupei Yang , Shiqi Liu , Mengyun Wang , Caiyun Peng , Bin Liu , Wei Wang , Huanghe Yu

Abnormal activation of macrophages and osteoclasts (OCs) contributes significantly to rheumatoid arthritis (RA) development by secretion of numerous inflammatory factors. Notably, these cells exhibit significant upregulation of folate receptor proteins on their surfaces. Unfortunately, there is a current lack of safe and effective therapeutic drugs for RA. Xuetongsu (XTS), a triterpenoid compound extracted from Kadsura heteroclita Roxb Craib, has demonstrated the ability to significantly inhibit the proliferation of RA fibroblast-like synoviocytes (RAFLS). However, its clinical application is hampered by poor targeting and short half-life. To address these drawbacks, we previously developed a nano-drug system named HRPS nanoparticles (NPs), which effectively targets RAFLS and inhibits synovial hyperplasia. However, this system overlooked the essential role of OCs in RA-related bone destruction. Therefore, we designed a novel folate-modified biomimetic Prussian blue (PB)-XTS NP (FMPX NP) for the selective delivery of XTS into inflammatory macrophages and OCs. The NP exhibits an excellent photothermal effect when assisted by laser irradiation, facilitating targeted release of XTS within inflammatory macrophages and OCs. The synergistic anti-inflammatory and reactive oxygen species scavenging effects of PB NPs and XTS are mediated by the inhibition of the NF-κB signaling pathway in inflammatory macrophages and RANK/RANKL/NFATc1 signaling pathway in OCs. In vivo experiments showed that FMPX NPs extended the half-life of XTS by 2.32 times, decreased hind foot swelling from 12.10 ± 0.49 mm to 8.24 ± 0.09 mm in the model group, and prevented bone damage. In conclusion, this study introduces a novel dual-targeted nano-based therapy for RA joints and highlights its potential for biochemical photothermal triple therapy for RA. FMPX NPs inhibit arthritis-related inflammation and bone destruction through a dual-target strategy, providing new insights for targeted drug therapies in clinical RA treatment.

巨噬细胞和破骨细胞（OCs）的异常激活通过分泌多种炎症因子在类风湿关节炎（RA）的发展中起着重要作用。值得注意的是，这些细胞表面叶酸受体蛋白显著上调。不幸的是，目前缺乏安全有效的类风湿性关节炎治疗药物。雪通素（XTS）是一种从鹿角草（Kadsura heteroclita Roxb Craib）中提取的三萜化合物，已被证明能够显著抑制RA成纤维细胞样滑膜细胞（RAFLS）的增殖。但其靶向性差、半衰期短，阻碍了其临床应用。为了解决这些问题，我们之前开发了一种名为HRPS纳米颗粒（NPs）的纳米药物系统，它可以有效地靶向RAFLS并抑制滑膜增生。然而，该系统忽略了OCs在ra相关骨破坏中的重要作用。因此，我们设计了一种新的叶酸修饰的仿生普鲁士蓝(PB)-XTS NP (FMPX NP)，用于选择性地将XTS递送到炎性巨噬细胞和oc中。NP在激光照射下表现出良好的光热效应，促进炎症性巨噬细胞和oc内XTS的靶向释放。PB NPs和XTS的协同抗炎和活性氧清除作用是通过抑制炎性巨噬细胞中NF-κB信号通路和OCs中RANK/RANKL/NFATc1信号通路介导的。体内实验表明，FMPX NPs能使XTS半衰期延长2.32倍，使模型组大鼠后足肿胀从12.10±0.49 mm减少到8.24±0.09 mm，并能防止骨损伤。综上所述，本研究介绍了一种新型的双靶向纳米治疗RA关节，并强调了其生物化学光热三联治疗RA的潜力。FMPX NPs通过双靶点策略抑制关节炎相关炎症和骨破坏，为临床治疗RA的靶向药物治疗提供了新的见解。

{"title":"Multifunctional Prussian blue nanoparticles loading with Xuetongsu for efficient rheumatoid arthritis therapy through targeting inflammatory macrophages and osteoclasts","authors":"Yasi Deng , Bin Li , Hao Zheng , Ling Liang , Yupei Yang , Shiqi Liu , Mengyun Wang , Caiyun Peng , Bin Liu , Wei Wang , Huanghe Yu","doi":"10.1016/j.ajps.2025.101037","DOIUrl":"10.1016/j.ajps.2025.101037","url":null,"abstract":"<div><div>Abnormal activation of macrophages and osteoclasts (OCs) contributes significantly to rheumatoid arthritis (RA) development by secretion of numerous inflammatory factors. Notably, these cells exhibit significant upregulation of folate receptor proteins on their surfaces. Unfortunately, there is a current lack of safe and effective therapeutic drugs for RA. Xuetongsu (XTS), a triterpenoid compound extracted from <em>Kadsura heteroclita</em> Roxb Craib, has demonstrated the ability to significantly inhibit the proliferation of RA fibroblast-like synoviocytes (RAFLS). However, its clinical application is hampered by poor targeting and short half-life. To address these drawbacks, we previously developed a nano-drug system named HRPS nanoparticles (NPs), which effectively targets RAFLS and inhibits synovial hyperplasia. However, this system overlooked the essential role of OCs in RA-related bone destruction. Therefore, we designed a novel folate-modified biomimetic Prussian blue (PB)-XTS NP (FMPX NP) for the selective delivery of XTS into inflammatory macrophages and OCs. The NP exhibits an excellent photothermal effect when assisted by laser irradiation, facilitating targeted release of XTS within inflammatory macrophages and OCs. The synergistic anti-inflammatory and reactive oxygen species scavenging effects of PB NPs and XTS are mediated by the inhibition of the NF-κB signaling pathway in inflammatory macrophages and RANK/RANKL/NFATc1 signaling pathway in OCs. <em>In vivo</em> experiments showed that FMPX NPs extended the half-life of XTS by 2.32 times, decreased hind foot swelling from 12.10 ± 0.49 mm to 8.24 ± 0.09 mm in the model group, and prevented bone damage. In conclusion, this study introduces a novel dual-targeted nano-based therapy for RA joints and highlights its potential for biochemical photothermal triple therapy for RA. FMPX NPs inhibit arthritis-related inflammation and bone destruction through a dual-target strategy, providing new insights for targeted drug therapies in clinical RA treatment.</div></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"20 3","pages":"Article 101037"},"PeriodicalIF":10.7,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144123782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advanced drug delivery platforms target cancer stem cells 先进的药物输送平台靶向癌症干细胞

IF 10.7 1区医学 Q1 PHARMACOLOGY & PHARMACY

Asian Journal of Pharmaceutical Sciences

Pub Date : 2025-02-19 DOI: 10.1016/j.ajps.2025.101036

MirAhmad Mazloomi , Abolfazl Doustmihan , Sajjad Alimohammadvand , Hamed Hamishehkar , Michael R. Hamblin , Rana Jahanban Esfahlan

Cancer stem cells (CSCs) are a major challenge in cancer therapy. Stem cell-like cells form a unique subpopulation within many tumors, which govern the degree of malignancy by promoting metastasis, recurrence, heterogeneity, and resistance to drug and radiation. Furthermore, these cells can persist in patients even after undergoing multiple cycles of conventional cancer therapy via dormancy, where they no longer dividing but remain active. These may cause cancer recurrence at any time, even years after a supposed cure, and remain invisible to the immune system. Targeting specific surface markers, signaling pathways and tumor microenvironment, which all have a significant effect on CSC function and maintenance, could help to eradicate CSCs and improve patient survival. Combinations of traditional therapies with nano-based drug delivery systems can efficiently target CSCs. Considering the biology and properties of CSCs, we classify recent approaches involving nanoparticle engineering, extracellular matrix modulation, cocktail strategies, multi-stage therapy, CSC defanging, Trojan horse systems, targeted therapy and organelle targeting. We highlight the most recent advances in nanocarrier design and drug delivery technologies to target CSCs, combined with conventional treatment in preclinical and clinical trials. The prospects of these approaches for CSCs elimination and recurrent cancer treatment are discussed.

肿瘤干细胞（CSCs）是癌症治疗中的一个主要挑战。干细胞样细胞在许多肿瘤中形成一个独特的亚群，通过促进转移、复发、异质性和对药物和放疗的抵抗来控制恶性程度。此外，即使经过多次常规癌症治疗后，这些细胞也能在患者体内持续存在，因为它们不再分裂，但仍保持活性。这些可能在任何时候导致癌症复发，甚至在所谓的治愈多年后，免疫系统仍然不可见。靶向特异性表面标记物、信号通路和肿瘤微环境对CSC功能和维持均有显著影响，有助于根除CSC，提高患者生存率。传统疗法与纳米药物传递系统的结合可以有效地靶向csc。考虑到CSC的生物学和特性，我们对最近的方法进行了分类，包括纳米颗粒工程、细胞外基质调节、鸡尾酒策略、多阶段治疗、CSC去毒化、特洛伊木马系统、靶向治疗和细胞器靶向。我们重点介绍了靶向CSCs的纳米载体设计和药物输送技术的最新进展，并结合临床前和临床试验中的常规治疗。讨论了这些方法在消除CSCs和治疗复发性癌症中的应用前景。

{"title":"Advanced drug delivery platforms target cancer stem cells","authors":"MirAhmad Mazloomi , Abolfazl Doustmihan , Sajjad Alimohammadvand , Hamed Hamishehkar , Michael R. Hamblin , Rana Jahanban Esfahlan","doi":"10.1016/j.ajps.2025.101036","DOIUrl":"10.1016/j.ajps.2025.101036","url":null,"abstract":"<div><div>Cancer stem cells (CSCs) are a major challenge in cancer therapy. Stem cell-like cells form a unique subpopulation within many tumors, which govern the degree of malignancy by promoting metastasis, recurrence, heterogeneity, and resistance to drug and radiation. Furthermore, these cells can persist in patients even after undergoing multiple cycles of conventional cancer therapy via dormancy, where they no longer dividing but remain active. These may cause cancer recurrence at any time, even years after a supposed cure, and remain invisible to the immune system. Targeting specific surface markers, signaling pathways and tumor microenvironment, which all have a significant effect on CSC function and maintenance, could help to eradicate CSCs and improve patient survival. Combinations of traditional therapies with nano-based drug delivery systems can efficiently target CSCs. Considering the biology and properties of CSCs, we classify recent approaches involving nanoparticle engineering, extracellular matrix modulation, cocktail strategies, multi-stage therapy, CSC defanging, Trojan horse systems, targeted therapy and organelle targeting. We highlight the most recent advances in nanocarrier design and drug delivery technologies to target CSCs, combined with conventional treatment in preclinical and clinical trials. The prospects of these approaches for CSCs elimination and recurrent cancer treatment are discussed.</div></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"20 3","pages":"Article 101036"},"PeriodicalIF":10.7,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144115585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dual-responsive and NIR-triggered detachable nanoplatform for integrated thrombolytic and antiplatelet therapy 用于溶栓和抗血小板综合治疗的双响应和nir触发可拆卸纳米平台

IF 11.9 1区医学 Q1 PHARMACOLOGY & PHARMACY

Asian Journal of Pharmaceutical Sciences

Pub Date : 2025-02-12 DOI: 10.1016/j.ajps.2025.101035

Huijuan Zhang , Zijun Qi , Chaoqun Wang , Yingmei Tian , Lin Hou

To develop an efficient thrombolytic therapy approach that addresses the limitations of current fibrinolytic drugs, such as short half-life, weak thrombus specificity and poor penetration ability, we constructed a NIR-triggered detachable nanoplatform (PA/UK@IcpLipo) using thin-film hydration method. It was designed to integrate attack and defense mechanisms for thrombolytic therapy. This platform can actively identify thrombi by binding to GPIIb-IIIa receptors overexpressed on activated platelets. Upon NIR laser activation and interaction with thrombin in the thrombotic microenvironment, the thermosensitive liposomes rupture, releasing the PA/UK core for deep penetration into the thrombus. Our results showed that the PA/UK@IcpLipo nanoplatform efficiently promoted rapid thrombolysis under the action of UK (attack), followed by PA exerting an antiplatelet aggregation effect (defense). This dual-action approach significantly improved vascular reperfusion rates. The NIR-triggered detachable nanoplatform offered a promising solution for enhanced thrombolysis efficiency and reduced bleeding risk, addressing critical limitations of current fibrinolytic therapies.

为了开发一种有效的溶栓治疗方法，解决当前溶栓药物半衰期短、血栓特异性弱和渗透能力差的局限性，我们利用薄膜水化方法构建了一个nir触发的可分离纳米平台（PA/UK@IcpLipo）。它旨在整合溶栓治疗的攻击和防御机制。该平台可以通过结合活化血小板上过表达的GPIIb-IIIa受体来主动识别血栓。在近红外激光激活并与血栓微环境中的凝血酶相互作用后，热敏脂质体破裂，释放PA/UK核心深入血栓。我们的研究结果表明，PA/UK@IcpLipo纳米平台在UK（攻击）作用下有效促进快速溶栓，随后PA发挥抗血小板聚集作用（防御）。这种双作用方法显著提高了血管再灌注率。nir触发的可拆卸纳米平台为提高溶栓效率和降低出血风险提供了一个有希望的解决方案，解决了当前纤溶治疗的关键局限性。

{"title":"Dual-responsive and NIR-triggered detachable nanoplatform for integrated thrombolytic and antiplatelet therapy","authors":"Huijuan Zhang , Zijun Qi , Chaoqun Wang , Yingmei Tian , Lin Hou","doi":"10.1016/j.ajps.2025.101035","DOIUrl":"10.1016/j.ajps.2025.101035","url":null,"abstract":"<div><div>To develop an efficient thrombolytic therapy approach that addresses the limitations of current fibrinolytic drugs, such as short half-life, weak thrombus specificity and poor penetration ability, we constructed a NIR-triggered detachable nanoplatform (PA/UK@IcpLipo) using thin-film hydration method. It was designed to integrate attack and defense mechanisms for thrombolytic therapy. This platform can actively identify thrombi by binding to GPIIb-IIIa receptors overexpressed on activated platelets. Upon NIR laser activation and interaction with thrombin in the thrombotic microenvironment, the thermosensitive liposomes rupture, releasing the PA/UK core for deep penetration into the thrombus. Our results showed that the PA/UK@IcpLipo nanoplatform efficiently promoted rapid thrombolysis under the action of UK (attack), followed by PA exerting an antiplatelet aggregation effect (defense). This dual-action approach significantly improved vascular reperfusion rates. The NIR-triggered detachable nanoplatform offered a promising solution for enhanced thrombolysis efficiency and reduced bleeding risk, addressing critical limitations of current fibrinolytic therapies.</div></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"20 4","pages":"Article 101035"},"PeriodicalIF":11.9,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144721768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in nanotechnology for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease 纳米技术在代谢功能障碍相关脂肪变性肝病诊断和治疗中的进展

IF 10.7 1区医学 Q1 PHARMACOLOGY & PHARMACY

Asian Journal of Pharmaceutical Sciences

Pub Date : 2025-02-09 DOI: 10.1016/j.ajps.2025.101025

Fenfen Li , Ruyan Yuan , Jiamin Zhang , Bing Su , Xiaolong Qi

Metabolic dysfunction-associated steatotic liver disease (MASLD) has a high global incidence and associated with increased lipid accumulation in hepatocytes, elevated hepatic enzyme levels, liver fibrosis, and hepatic carcinoma. Despite decades of research and significant advancements, the treatment of MASLD still faces formidable challenges. Nanoprobes for diagnostics and nanomedicine for targeted drug delivery to the liver present promising options for MASLD diagnosis and treatment, enhancing both imaging contrast and bioavailability. Here, we review recent advances in nanotechnology applied to MASLD diagnosis and treatment, specifically focusing on drug delivery systems targeting hepatocytes, hepatic stellate cells, Kupffer cells, and liver sinusoidal endothelial cells. This review aims to provide an overview of nanomedicine's potential in early MASLD diagnosis and therapeutic interventions, addressing related complications.

代谢功能障碍相关性脂肪性肝病（MASLD）在全球发病率很高，与肝细胞内脂质蓄积增加、肝酶水平升高、肝纤维化和肝癌有关。尽管经过数十年的研究并取得了重大进展，但 MASLD 的治疗仍面临严峻挑战。用于诊断的纳米探针和用于肝脏靶向给药的纳米药物为 MASLD 的诊断和治疗提供了前景广阔的选择，既增强了成像对比度，又提高了生物利用度。在此，我们回顾了应用于 MASLD 诊断和治疗的纳米技术的最新进展，特别关注针对肝细胞、肝星状细胞、Kupffer 细胞和肝窦内皮细胞的给药系统。本综述旨在概述纳米医学在早期 MASLD 诊断和治疗干预方面的潜力，并探讨相关并发症。

引用次数: 0

Microalgae-carrying nanomedicine for bioadhesive drug delivery for treating chemotherapy-induced intestinal injury 微藻载纳米药物用于生物黏附给药治疗化疗引起的肠道损伤

IF 10.7 1区医学 Q1 PHARMACOLOGY & PHARMACY

Asian Journal of Pharmaceutical Sciences

Pub Date : 2025-02-08 DOI: 10.1016/j.ajps.2025.101024

Jie Chen , Bing Wang , Lan Shen , Yongzhuo Huang

Gastrointestinal tract toxicity represents a serious adverse effect of chemotherapy, leading to reduced quality of life and survival. For instance, irinotecan (CPT-11) usually causes severe gastrointestinal toxicity, with a lack of effective therapeutic interventions, making treatment often unsustainable. Therefore, development of an effective and safe therapy is crucial for improving chemotherapy efficacy and the patients’ quality of life. In this work, we developed a novel approach involving the helical-shaped cyanobacterium microalgae, Spirulina platensis (SP), to carry the bornyl acetate (BA)-loaded chitosan nanoparticles to enhance drug retention in the small intestine. We demonstrated the protection effect of BA against chemotherapy-induced intestinal injury using an epithelial cell model. In a mouse model, orally administered BA-ChNPs@SP accumulated in the small intestine and attenuated inflammation by reducing dsDNA release and oxidative stress. This was concomitant with the restoration of the intestinal barrier and modulation of the immune microenvironment. This work suggests the promise of the microalgae-carrying nanomedicine strategy for treatment of intestinal diseases, emphasizing its potential in addressing chemotherapy-induced gastrointestinal complications.

胃肠道毒性是化疗的严重不良反应，导致生活质量和生存率下降。例如，伊立替康（CPT-11）通常会引起严重的胃肠道毒性，缺乏有效的治疗干预措施，使治疗往往不可持续。因此，开发一种有效、安全的治疗方法对于提高化疗疗效和患者的生活质量至关重要。在这项工作中，我们开发了一种涉及螺旋形蓝藻微藻螺旋藻（SP）的新方法，以携带负载乙酸龙脑酯（BA）的壳聚糖纳米颗粒来增强药物在小肠中的保留。我们利用上皮细胞模型证明了BA对化疗诱导的肠道损伤的保护作用。在小鼠模型中，口服BA-ChNPs@SP在小肠中积累，并通过减少dsDNA释放和氧化应激来减轻炎症。这是伴随着肠道屏障的恢复和免疫微环境的调节。这项工作表明了微藻纳米药物治疗肠道疾病的前景，强调了其在解决化疗引起的胃肠道并发症方面的潜力。

{"title":"Microalgae-carrying nanomedicine for bioadhesive drug delivery for treating chemotherapy-induced intestinal injury","authors":"Jie Chen , Bing Wang , Lan Shen , Yongzhuo Huang","doi":"10.1016/j.ajps.2025.101024","DOIUrl":"10.1016/j.ajps.2025.101024","url":null,"abstract":"<div><div>Gastrointestinal tract toxicity represents a serious adverse effect of chemotherapy, leading to reduced quality of life and survival. For instance, irinotecan (CPT-11) usually causes severe gastrointestinal toxicity, with a lack of effective therapeutic interventions, making treatment often unsustainable. Therefore, development of an effective and safe therapy is crucial for improving chemotherapy efficacy and the patients’ quality of life. In this work, we developed a novel approach involving the helical-shaped cyanobacterium microalgae, <em>Spirulina platensis</em> (SP), to carry the bornyl acetate (BA)-loaded chitosan nanoparticles to enhance drug retention in the small intestine. We demonstrated the protection effect of BA against chemotherapy-induced intestinal injury using an epithelial cell model. In a mouse model, orally administered BA-ChNPs@SP accumulated in the small intestine and attenuated inflammation by reducing dsDNA release and oxidative stress. This was concomitant with the restoration of the intestinal barrier and modulation of the immune microenvironment. This work suggests the promise of the microalgae-carrying nanomedicine strategy for treatment of intestinal diseases, emphasizing its potential in addressing chemotherapy-induced gastrointestinal complications.</div></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"20 2","pages":"Article 101024"},"PeriodicalIF":10.7,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143642177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Implantable devices for resected glioblastoma therapy 胶质母细胞瘤切除治疗的植入式装置

IF 10.7 1区医学 Q1 PHARMACOLOGY & PHARMACY

Asian Journal of Pharmaceutical Sciences

Pub Date : 2025-02-08 DOI: 10.1016/j.ajps.2025.101034

Xiaoyu Chang , Hui Guo , Yunqian Li , Jianxun Ding

Glioblastoma (GBM) is a highly infiltrative brain tumor. The treatment of GBM is challenging due to the existence of blood brain barrier, its highly invasive nature, and its heterogeneity. Given the limitations of conventional therapies, this Perspective explores the development trajectory of implantable devices, highlighting the advantages of current models. With the progression in research, these implantable devices certainly hold promising potential for GBM therapy.

胶质母细胞瘤（GBM）是一种高度浸润的脑肿瘤。由于血脑屏障的存在、高侵袭性和异质性，GBM的治疗具有挑战性。鉴于传统疗法的局限性，本视角探讨了植入式装置的发展轨迹，突出了当前模型的优势。随着研究的进展，这些植入式装置在GBM治疗中肯定具有很大的潜力。

引用次数: 0

Tailoring carrier-free nanoparticles based on natural small molecule assembly for synergistic anti-tumor efficacy 基于天然小分子组装的裁剪无载体纳米颗粒协同抗肿瘤功效

IF 10.7 1区医学 Q1 PHARMACOLOGY & PHARMACY

Asian Journal of Pharmaceutical Sciences

Pub Date : 2025-02-01 DOI: 10.1016/j.ajps.2024.100992

Di Wu , Bin Zhou , Ying Liu , Xiao Zhu , Bin Li , Hongshan Liang

Interfacial modular assemblies of versatile polyphenols have attracted widespread interest in surface and materials engineering. In this study, natural polyphenol (tannic acid, TA) and nobiletin (NOB) can directly form binary carrier-free spherical nanoparticles (NT NPs) through synergistically driven by a variety of interactions (such as hydrogen bonding, oxidative reactions, etc.). The synthesis involves polyphenolic deposition on hydrophobic NOB nanoaggregates, followed by in situ oxidative self-polymerization. Interestingly, the assembled NT NPs exhibit controllable and dynamic changes in particle size during the initial stage. Ultimately, uniform and spherical NT NPs appear stable, with high loading capability, enabling incorporated NOB to preserve their function. Furthermore, in vitro evaluations demonstrate that the rational combination of polyphenol module and NOB can induce apoptosis and inhibit tumor metastasis for both lung cancer H1299 and human fibrosarcoma HT1080 cell lines. Notably, the optimized NT48 NPs were then verified in vivo experiments to achieve a promising synergistic anti-tumor efficacy. These findings not only provide new opportunities for the streamlined and sensible engineering of future polyphenol-based biomaterials, but also open up new prospects for the design of small-molecule nature phytochemicals.

多酚类化合物的界面模块化组装在表面和材料工程领域引起了广泛的关注。本研究中，天然多酚（单宁酸，TA）与皂素（NOB）在多种相互作用（如氢键、氧化反应等）的协同驱动下，可直接形成二元无载流子球形纳米颗粒（NT NPs）。合成过程包括在疏水NOB纳米聚集体上沉积多酚，然后进行原位氧化自聚合。有趣的是，组装的NT NPs在初始阶段表现出可控和动态的粒径变化。最终，均匀和球形的NT NPs看起来稳定，具有高负载能力，使加入NOB能够保持其功能。此外，体外实验表明，多酚模块与NOB的合理组合对肺癌H1299和人纤维肉瘤HT1080细胞系均具有诱导凋亡和抑制肿瘤转移的作用。值得注意的是，优化后的NT48 NPs在体内实验中得到了验证，具有很好的协同抗肿瘤功效。这些发现不仅为未来基于多酚的生物材料的流线型和可感知工程提供了新的机会，而且为小分子天然植物化学物质的设计开辟了新的前景。

{"title":"Tailoring carrier-free nanoparticles based on natural small molecule assembly for synergistic anti-tumor efficacy","authors":"Di Wu , Bin Zhou , Ying Liu , Xiao Zhu , Bin Li , Hongshan Liang","doi":"10.1016/j.ajps.2024.100992","DOIUrl":"10.1016/j.ajps.2024.100992","url":null,"abstract":"<div><div>Interfacial modular assemblies of versatile polyphenols have attracted widespread interest in surface and materials engineering. In this study, natural polyphenol (tannic acid, TA) and nobiletin (NOB) can directly form binary carrier-free spherical nanoparticles (NT NPs) through synergistically driven by a variety of interactions (such as hydrogen bonding, oxidative reactions, etc.). The synthesis involves polyphenolic deposition on hydrophobic NOB nanoaggregates, followed by <em>in situ</em> oxidative self-polymerization. Interestingly, the assembled NT NPs exhibit controllable and dynamic changes in particle size during the initial stage. Ultimately, uniform and spherical NT NPs appear stable, with high loading capability, enabling incorporated NOB to preserve their function. Furthermore, <em>in vitro</em> evaluations demonstrate that the rational combination of polyphenol module and NOB can induce apoptosis and inhibit tumor metastasis for both lung cancer H1299 and human fibrosarcoma HT1080 cell lines. Notably, the optimized NT48 NPs were then verified <em>in vivo</em> experiments to achieve a promising synergistic anti-tumor efficacy. These findings not only provide new opportunities for the streamlined and sensible engineering of future polyphenol-based biomaterials, but also open up new prospects for the design of small-molecule nature phytochemicals.</div></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"20 1","pages":"Article 100992"},"PeriodicalIF":10.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143102271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Polymeric nanocarriers for therapeutic gene delivery 用于治疗性基因传递的高分子纳米载体

IF 10.7 1区医学 Q1 PHARMACOLOGY & PHARMACY

Asian Journal of Pharmaceutical Sciences

Pub Date : 2025-02-01 DOI: 10.1016/j.ajps.2025.101015

Jiayuan Zhang , Xinyu Yang , Zhichao Chang , Wenwei Zhu , Yuhua Ma , Haisheng He

The recent commercialization of gene products has sparked significant interest in gene therapy, necessitating efficient and precise gene delivery via various vectors. Currently, viral vectors and lipid-based nanocarriers are the predominant choices and have been extensively investigated and reviewed. Beyond these vectors, polymeric nanocarriers also hold the promise in therapeutic gene delivery owing to their versatile functionalities, such as improving the stability, cellar uptake and endosomal escape of nucleic acid drugs, along with precise delivery to targeted tissues. This review presents a brief overview of the status quo of the emerging polymeric nanocarriers for therapeutic gene delivery, focusing on key cationic polymers, nanocarrier types, and preparation methods. It also highlights targeted diseases, strategies to improve delivery efficiency, and potential future directions in this research area. The review is hoped to inspire the development, optimization, and clinical translation of highly efficient polymeric nanocarriers for therapeutic gene delivery.

最近基因产品的商业化引发了人们对基因治疗的极大兴趣，需要通过各种载体高效和精确地传递基因。目前，病毒载体和基于脂质的纳米载体是主要的选择，并得到了广泛的研究和综述。除了这些载体之外，聚合物纳米载体由于其多功能，如提高核酸药物的稳定性、细胞吸收和内体逃逸，以及精确递送到目标组织，在治疗性基因递送方面也有希望。本文综述了用于治疗性基因传递的新型高分子纳米载体的研究现状，重点介绍了主要的阳离子聚合物、纳米载体类型和制备方法。它还强调了目标疾病，提高递送效率的策略，以及该研究领域潜在的未来方向。该综述希望对高效高分子纳米载体的开发、优化和临床转化提供启发。

引用次数: 0

Hyaluronic acid conjugates with controlled oleic acid substitution as new nanomaterials for improving ocular co-delivery of cyclosporine A and oleic acid 透明质酸与油酸取代缀合物作为改善环孢素A与油酸眼部共递送的新型纳米材料

IF 10.7 1区医学 Q1 PHARMACOLOGY & PHARMACY

Asian Journal of Pharmaceutical Sciences

Pub Date : 2025-02-01 DOI: 10.1016/j.ajps.2024.101009

Hai V. Ngo , Hy D. Nguyen , Beom-Jin Lee

A structural conjugate (HOC) of polysaccharide, hyaluronic acid (HA) with different ratios of oleic acid (OA) via cystamine (CYS) linker as a new ocular biomaterial was developed. The HOCs with controlled degrees of substitution of OA (4.6 %, 8.3 % and 12.2 %) were synthesized to form self-assembled HA-CYS-OA nanoparticles (HONs, HON1, HON2, HON3). A poorly water-soluble cyclosporine A (CsA) to be used for the treatment of multifactorial dry eye disease (DED) was chosen as model drug. CsA-loaded HONs exhibited improved solution transparency via solubilizing capacity of HON, and increased in vitro drug permeation compared to Restasis®. The physicochemical properties of CsA-loaded HONs such as nano behaviors, solution transparency, drug release, drug permeation and ocular cytocompatibility were highly variable according to the ratios of OA substitution. Interestingly, this CsA-loaded HON1 as optimal ocular nanoformulation showed markedly augmented macrophage polarization into the M2 phenotype, downregulated the expression of proinflammatory cytokines levels in LPS-induced M1 macrophage, and effectively inhibited VEGF-induced endothelial cell proliferation and capillary-like tube formation by the synergistic effect of CsA and HON1 containing OA at the same time. Collectively, the current fatty acid conjugated to HA, named fattigation platform, providing the roles and physicochemical properties via structural features of HA could be a promising co-delivery strategy of drug and fatty acid for DED and other ophthalmic disease treatments.

通过半胱胺（CYS）连接剂，制备了透明质酸（HA）与不同比例油酸（OA）的结构偶联物（HOC），作为一种新型眼部生物材料。合成了OA取代度可控的hoc(4.6%， 8.3%和12.2%)，形成了自组装的HA-CYS-OA纳米粒子（HONs, HON1, HON2, HON3）。选择一种用于治疗多因素干眼病（DED）的低水溶性环孢素A （CsA）作为模型药物。与Restasis®相比，csa负载的HON通过HON的增溶能力提高了溶液透明度，并增加了体外药物渗透。负载csa的HONs的理化性质，如纳米行为、溶液透明度、药物释放、药物渗透和眼细胞相容性等，随着OA取代率的不同而发生很大变化。有趣的是，这种负载CsA的HON1作为最佳眼部纳米制剂，可以显著增强巨噬细胞向M2表型的极化，下调lps诱导的M1巨噬细胞中促炎细胞因子的表达水平，同时通过CsA和含OA的HON1的协同作用，有效抑制vegf诱导的内皮细胞增殖和毛细血管样管的形成。综上所述，目前与透明质酸缀合的脂肪酸被称为脂化平台，通过透明质酸的结构特征提供了其作用和理化性质，可能是一种很有前景的药物与脂肪酸共给药策略，用于DED和其他眼科疾病的治疗。

{"title":"Hyaluronic acid conjugates with controlled oleic acid substitution as new nanomaterials for improving ocular co-delivery of cyclosporine A and oleic acid","authors":"Hai V. Ngo , Hy D. Nguyen , Beom-Jin Lee","doi":"10.1016/j.ajps.2024.101009","DOIUrl":"10.1016/j.ajps.2024.101009","url":null,"abstract":"<div><div>A structural conjugate (HOC) of polysaccharide, hyaluronic acid (HA) with different ratios of oleic acid (OA) via cystamine (CYS) linker as a new ocular biomaterial was developed. The HOCs with controlled degrees of substitution of OA (4.6 %, 8.3 % and 12.2 %) were synthesized to form self-assembled HA-CYS-OA nanoparticles (HONs, HON1, HON2, HON3). A poorly water-soluble cyclosporine A (CsA) to be used for the treatment of multifactorial dry eye disease (DED) was chosen as model drug. CsA-loaded HONs exhibited improved solution transparency via solubilizing capacity of HON, and increased <em>in vitro</em> drug permeation compared to Restasis®. The physicochemical properties of CsA-loaded HONs such as nano behaviors, solution transparency, drug release, drug permeation and ocular cytocompatibility were highly variable according to the ratios of OA substitution. Interestingly, this CsA-loaded HON1 as optimal ocular nanoformulation showed markedly augmented macrophage polarization into the M2 phenotype, downregulated the expression of proinflammatory cytokines levels in LPS-induced M1 macrophage, and effectively inhibited VEGF-induced endothelial cell proliferation and capillary-like tube formation by the synergistic effect of CsA and HON1 containing OA at the same time. Collectively, the current fatty acid conjugated to HA, named fattigation platform, providing the roles and physicochemical properties via structural features of HA could be a promising co-delivery strategy of drug and fatty acid for DED and other ophthalmic disease treatments.</div></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"20 1","pages":"Article 101009"},"PeriodicalIF":10.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143102270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent advances in zeolitic imidazolate frameworks as drug delivery systems for cancer therapy 沸石咪唑盐框架作为癌症治疗药物递送系统的最新进展

IF 10.7 1区医学 Q1 PHARMACOLOGY & PHARMACY

Asian Journal of Pharmaceutical Sciences

Pub Date : 2025-02-01 DOI: 10.1016/j.ajps.2025.101017

Yuhan Wang , Yixin Tang , Lei Guo , Xi Yang , Shanli Wu , Ying Yue , Caina Xu

Biological nanotechnologies based on functional nanoplatforms have synergistically catalyzed the emergence of cancer therapies. As a subtype of metal-organic frameworks (MOFs), zeolitic imidazolate frameworks (ZIFs) have exploded in popularity in the field of biomaterials as excellent protective materials with the advantages of conformational flexibility, thermal and chemical stability, and functional controllability. With these superior properties, the applications of ZIF-based materials in combination with various therapies for cancer treatment have grown rapidly in recent years, showing remarkable achievements and great potential. This review elucidates the recent advancements in the use of ZIFs as drug delivery agents for cancer therapy. The structures, synthesis methods, properties, and various modifiers of ZIFs used in oncotherapy are presented. Recent advances in the application of ZIF-based nanoparticles as single or combination tumor treatments are reviewed. Furthermore, the future prospects, potential limitations, and challenges of the application of ZIF-based nanomaterials in cancer treatment are discussed. We except to fully explore the potential of ZIF-based materials to present a clear outline for their application as an effective cancer treatment to help them achieve early clinical application.

基于功能性纳米平台的生物纳米技术协同催化了癌症治疗的出现。作为金属有机骨架（MOFs）的一个亚型，沸石咪唑酸骨架（ZIFs）具有构象柔韧性、热稳定性和化学稳定性以及功能可控性等优点，在生物材料领域得到了广泛的应用。凭借这些优越的性能，近年来，zif基材料与各种治疗方法结合在癌症治疗中的应用迅速增长，显示出显著的成就和巨大的潜力。本文综述了zif作为癌症治疗药物递送剂的最新进展。介绍了用于肿瘤治疗的zif的结构、合成方法、性质和各种改性剂。综述了近年来基于zif的纳米颗粒在单一或联合肿瘤治疗中的应用进展。此外，还讨论了zif基纳米材料在癌症治疗中的应用前景、潜在局限性和挑战。我们需要充分挖掘基于zif的材料的潜力，为其作为一种有效的癌症治疗方法的应用提供一个清晰的轮廓，帮助其早日实现临床应用。

{"title":"Recent advances in zeolitic imidazolate frameworks as drug delivery systems for cancer therapy","authors":"Yuhan Wang , Yixin Tang , Lei Guo , Xi Yang , Shanli Wu , Ying Yue , Caina Xu","doi":"10.1016/j.ajps.2025.101017","DOIUrl":"10.1016/j.ajps.2025.101017","url":null,"abstract":"<div><div>Biological nanotechnologies based on functional nanoplatforms have synergistically catalyzed the emergence of cancer therapies. As a subtype of metal-organic frameworks (MOFs), zeolitic imidazolate frameworks (ZIFs) have exploded in popularity in the field of biomaterials as excellent protective materials with the advantages of conformational flexibility, thermal and chemical stability, and functional controllability. With these superior properties, the applications of ZIF-based materials in combination with various therapies for cancer treatment have grown rapidly in recent years, showing remarkable achievements and great potential. This review elucidates the recent advancements in the use of ZIFs as drug delivery agents for cancer therapy. The structures, synthesis methods, properties, and various modifiers of ZIFs used in oncotherapy are presented. Recent advances in the application of ZIF-based nanoparticles as single or combination tumor treatments are reviewed. Furthermore, the future prospects, potential limitations, and challenges of the application of ZIF-based nanomaterials in cancer treatment are discussed. We except to fully explore the potential of ZIF-based materials to present a clear outline for their application as an effective cancer treatment to help them achieve early clinical application.</div></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"20 1","pages":"Article 101017"},"PeriodicalIF":10.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143102274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0